HighVista Strategies’s Altimmune ALT Stock Holding History

HighVista Strategies’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-45,866	Closed	-$648K	–	120
2021 Q1	$648K	Sell	45,866 -26,512	-37%	-$429K	0.48%	52
2020 Q4	$816K	Buy	+72,378	New	+$853K	0.52%	43

Other funds holding ALT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HighVista Strategies's ALT Position: Q2 2021 in Review

HighVista Strategies sold out of Altimmune (ALT) in Q2 2021, closing a stake of 45,866 shares — an estimated $648K sold.

HighVista Strategies first reported a position in ALT in Q4 2020 and held it in 2 quarters. The position peaked at $816K in Q4 2020. 109 funds tracked by Wall St. Rank hold ALT as of Q2 2021.

HighVista Strategies reported no remaining Altimmune position as of Q2 2021 after selling out during the quarter.
HighVista Strategies sold 45,866 Altimmune shares in Q2 2021, an estimated $648K.
HighVista Strategies first reported a position in Altimmune in Q4 2020 and held it in 2 quarters.
HighVista Strategies's Altimmune position peaked at $816K in Q4 2020.
109 funds tracked by Wall St. Rank held Altimmune as of Q2 2021.

Based on HighVista Strategies's 13F filing for Q2 2021, filed 16 Aug 2021.